HDT BIO

We are a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. In 2014, the U.S. market for immune therapeutics was estimated at $1.4 billion and it is projected to grow to $27 billion by 2021. Assets in our portfolio include activators of innate and adaptive immune responses. A distinguishing factor to these is the formulation expertise which enables these technologies by targeting them to local and systemic sites in the body where they ar... e needed. Since they affect the host and not the pathogen it will be difficult for resistance to emerge. Thus, we see an opportunity to apply the latest technologies in immunology to expand the benefits of immunotherapy to all. Our founders are world leaders in the development of adjuvants and immune therapeutics and have developed a number of these immune stimulants in the past in their work with multiple successful spin-out exits. They are joined by experienced entrepreneurs with expertise in biotechnology operations, finance, intellectual property, legal and strategy.More